vidarabine has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| King, I; Li, Z; Liu, L; Song, BL; Zheng, LM | 1 |
| Koike, N; Mulé, JJ; Pilon-Thomas, S | 1 |
2 other study(ies) available for vidarabine and B16 Melanoma
| Article | Year |
|---|---|
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Injections, Intraperitoneal; Leukemia L1210; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Sulfonamides; Survival Analysis; Time Factors; Tumor Burden; Vidarabine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Immunologic Memory; Interferon-gamma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Vidarabine; Whole-Body Irradiation | 2008 |